Analystreport

Nabriva Therapeutics PLC - (NASDAQ: NBRV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $0.75 price target on the stock.

Nabriva Therapeutics plc - Ordinary Shares  (NBRV) 
Last nabriva therapeutics plc - ordinary shares earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.nabriva.com/investor-relations